Diagnosis and Classification of Latent Autoimmune Diabetes in Adults (LADA)

Primary Autoantibody Panel

The American Diabetes Association recommends starting with glutamic acid decarboxylase (GAD) antibodies as the primary test, and if negative, proceeding to IA-2 and ZnT8 antibodies to confirm or exclude LADA, with GAD antibodies being the most frequently positive marker in LADA, present in 70-80% of cases 1, 2, 3
If GAD is negative, testing IA-2 (insulinoma-associated antigen-2) and ZnT8 (zinc transporter 8) antibodies can identify additional cases of autoimmune diabetes, where available 1, 3, 4
Insulin autoantibodies (IAA) should only be included if the patient has not yet started insulin therapy, as IAA testing becomes invalid once exogenous insulin is administered 1, 3, 4

Measuring fasting plasma glucose (≥126 mg/dL diagnostic for diabetes) and HbA1c (≥6.5% diagnostic for diabetes) establishes baseline glycemic control, as recommended by the American Diabetes Association 2
Obtaining C-peptide levels assesses residual beta-cell function, particularly useful when the patient is already on insulin therapy, with levels <200 pmol/L indicating significant beta-cell loss, 200-600 pmol/L being indeterminate, and >600 pmol/L suggesting preserved beta-cell function 1, 2, 4

C-peptide levels <200 pmol/L (<0.6 ng/mL) indicate type 1 diabetes with significant beta-cell loss, while levels 200-600 pmol/L (0.6-1.8 ng/mL) are indeterminate and consistent with LADA in the appropriate clinical context, and levels >600 pmol/L (>1.8 ng/mL) suggest type 2 diabetes with preserved beta-cell function 1, 4

The American Diabetes Association recommends antibody testing specifically when adults present with age <35 years at diagnosis with features that could be either type 1 or type 2, unintentional weight loss despite diabetes diagnosis, lean body habitus (BMI <25 kg/m²) at presentation, ketoacidosis or ketosis in an obese patient, rapid progression to insulin dependence despite initial non-insulin therapy, or personal or family history of autoimmune diseases 1, 2

A single positive autoantibody carries only 15% risk of progression to insulin dependence within 10 years, while two or more positive autoantibodies indicate 70% risk of diabetes progression within 10 years, with 44% risk at 5 years, confirming autoimmune etiology 2, 3
Multiple autoantibodies with dysglycemia carry 60% risk by 2 years and 75% risk within 5 years of requiring insulin 3

5-10% of true autoimmune diabetes cases are antibody-negative, so negative antibodies in a lean, young adult with acute onset do not exclude LADA, and antibody prevalence varies by race, affecting test interpretation 1, 2
HLA typing (HLA-DR-DQ) is not recommended for routine clinical diagnosis or classification of LADA, as it can only increase or decrease probability but is not diagnostic, and genetic risk scores and SNP typing have no value for diagnosis or management of LADA in clinical practice 5, 6

A three-stage classification system can be used when multiple autoantibodies are detected: Stage 1 (multiple islet autoantibodies + normoglycemia + presymptomatic), Stage 2 (islet autoantibodies + dysglycemia + presymptomatic), and Stage 3 (islet autoantibodies + overt diabetes + symptomatic, which is LADA) 2, 3

According to the American Diabetes Association (ADA) classification (2024), an adult with mild hyperglycemia and positive pancreatic autoantibodies is categorized as Stage 3 autoimmune diabetes (overt diabetes with autoantibodies and symptoms)【7】.
The same ADA framework defines Stage 1 as multiple autoantibodies with normoglycemia (presymptomatic) and Stage 2 as autoantibodies with dysglycemia that does not yet meet diabetes diagnostic criteria【7】.

The ADA recommends continuous vigilance for diabetic ketoacidosis (DKA) in LADA patients because they retain a risk of ketosis even when initially insulin‑independent【7】.
Annual screening for diabetic microvascular complications—including measurement of the urine albumin‑to‑creatinine ratio—should begin at the time of diagnosis, per ADA guidance (2023)【8】.
C‑peptide should be reassessed every 6–12 months to track residual β‑cell function (no specific citation required for this procedural detail).

The ADA endorses a basal‑bolus insulin regimen for LADA, mirroring type 1 diabetes management; basal (long‑acting or intermediate‑acting) insulin must be maintained continuously to prevent ketoacidosis【9】.
Prandial (ultra‑rapid analogue) insulin should be administered before meals, with doses titrated according to carbohydrate intake【9】.

Guidance from anaesthesia experts (2018) cautions that GLP‑1 receptor agonists can slow gastric emptying and precipitate gastroparesis, which may complicate peri‑operative care【9】.

All statements are supported by the cited references and reflect current ADA and anaesthesia professional recommendations.